AR and cancer: In 2019, Professor Zhimin Shao’s team at the Affiliated Cancer Hospital of Fudan University, through an integrated analysis of genomic, transcriptomic, and clinical data of 465 patients with primary TNBC, classified TNBC into four subtypes: luminal androgen receptor (LAR), basal-like immunosuppressive (BLIS), mesenchymal (MES), and immune-modulated (IM) (12) (Figure 1).